Zomedica Corp (ZOM) is around the middle of the Drug Manufacturers - Specialty & Generic industry according to InvestorsObserver. ZOM received an overall rating of 19, which means that it scores higher than 19 percent of all stocks. Zomedica Corp also achieved a score of 53 in the Drug Manufacturers - Specialty & Generic industry, putting it above 53 percent of Drug Manufacturers - Specialty & Generic stocks. Drug Manufacturers - Specialty & Generic is ranked 143 out of the 148 industries.
What do These Ratings Mean?
Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 19 means the stock is more attractive than 19 percent of stocks.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.
What's Happening With Zomedica Corp Stock Today?
Zomedica Corp (ZOM) stock is down -4.12% while the S&P 500 is higher by 0.5% as of 2:45 PM on Thursday, Jun 10. ZOM is down -$0.04 from the previous closing price of $0.97 on volume of 25,878,104 shares. Over the past year the S&P 500 is higher by 32.94% while ZOM is higher by 342.86%. ZOM lost -$0.05 per share the over the last 12 months.